GSK is licensing out the liver disease drug linerixibat to the Italian pharma Alfasigma for $300 million upfront, weeks ahead of the pill’s March 24 PDUFA date.
The drug, which is …
Basecamp Research’s Trillion Gene Atlas will bring together genomic data from millions of species to guide AI-powered design of new medicines.
Plus, news about Eledon, Sobi, Ovid and CytomX: 🗓️ Ionis updates prion disease study timelines: The California oligonucleotide powerhouse has pushed back the primary completion
Johnson & Johnson secured an FDA approval on Wednesday for a psoriasis pill it expects to become a megablockbuster. Regulators gave the green light to
Johnson & Johnson’s much-anticipated oral IL-23 drug, icotrokinra, has claimed FDA approval as Icotyde for first-line treatment of plaque psoriasis.
Always be in the clinic — those are the “ABCs” of biotech, drug development veteran Briggs Morrison tells Endpoints News. And that’s precisely where Morrison’s
GSK is licensing out the liver disease drug linerixibat to the Italian pharma Alfasigma for $300 million upfront, weeks ahead of the pill’s March 24 PDUFA date.
The drug, which is …